Best of Breast: news for week ending 13 Sept 2013

A summary of the developments in breast cancer research from Google Alerts for the week ending 13 September 2013.

1.  Hormone therapy may NOT pose higher cancer risk in some women

“Taking hormones to treat the symptoms of menopause is thought to increase women’s risk of breast cancer, but this risk doesn’t rise equally in all women, a new study finds.

The increase in risk varies depending on a woman’s race, body mass index (BMI) and breast density, and some women may benefit from hormone therapy while facing little increase in cancer risk, the study found.”

2.  New test can help detect breast cancer a decade before it develops

“Imagine being able to detect breast cancer a decade before it develops.

Doctors are saying that dream may soon become a reality with a new test called ForeCYTE.”

3.  Researchers Focus on Likelihood of Breast Cancer Recurrence:

Seven tumor-specific genes appear to yield accurate prognosis, study says

“Researchers say they’ve identified a genetic indicator of the long-term risk of breast cancer recurrence.

They compared three gene signature methods of predicting the risk of recurrence in patients treated for estrogen-receptor (ER)-positive breast cancer. They found that only the breast cancer index (BCI) — a “biomarker” based on the expression levels of seven tumor-specific genes — accurately identifies patients who continues to be at risk for breast cancer recurrence after five years of treatment with either tamoxifen or anastrozole, a drug in the aromatase inhibitor class.

More than half the instances of recurrence in ER-positive breast cancer occur after five years of therapy with tamoxifen or anastrozole, so these findings are highly relevant to clinical management, study leader Dr. Dennis Sgroi, of the MGH Cancer Center, said in the news release.”

4.  Drug, Perjeta, Shows Promise for Early Stage Breast Cancer

“A drug already used to treat advanced breast cancer also appears to shrink early stage breast tumors, potentially offering women a first-of-its-kind treatment option, U.S. health regulators say.

If approved to treat early stage cancers, the drug, Perjeta, might result in less invasive surgical treatment — or no surgical treatment — for women with HER2-positive early stage breast cancer, Bloomberg News reported Tuesday.”


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s